Tsubota Laboratory Incorporated

坪田ラボ

Industry: Pharmaceutical
Market: Growth
Accounting standards: Japanese GAAP
Consolidation basis: Non-consolidated

Key metrics

Revenue(thousand JPY)

Mar 2022

640,921

Mar 2023

954,693

Mar 2024

673,532

Mar 2025

1,357,133

Operating profit(thousand JPY)

Mar 2022

136,169

Mar 2023

167,031

Mar 2024

-649,554

Mar 2025

235,467

Operating profit margin(%)

Mar 2022

21.25

Mar 2023

17.5

Mar 2024

-96.44

Mar 2025

17.35

Profit before tax(thousand JPY)

Mar 2022

202,340

Mar 2023

144,221

Mar 2024

-636,371

Mar 2025

281,049

Profit(thousand JPY)

Mar 2022

153,319

Mar 2023

90,181

Mar 2024

-641,317

Mar 2025

205,766

Total assets(thousand JPY)

Mar 2022

1,617,795

Mar 2023

2,672,961

Mar 2024

2,295,159

Mar 2025

2,503,123

Cash and cash equivalents(thousand JPY)

Mar 2022

1,174,929

Mar 2023

2,161,016

Mar 2024

1,883,400

Mar 2025

1,538,853

Cash flows from operating activities(thousand JPY)

Mar 2022

654,914

Mar 2023

28,491

Mar 2024

-301,350

Mar 2025

-317,754

Cash flows from investing activities(thousand JPY)

Mar 2022

-72,228

Mar 2023

-54,027

Mar 2024

-12,001

Mar 2025

-14,547

Cash flows from financing activities(thousand JPY)

Mar 2022

-18,530

Mar 2023

1,011,623

Mar 2024

35,736

Mar 2025

-12,246

Return on equity(%)

Mar 2022

22.96

Mar 2023

6.69

Mar 2024

Mar 2025

13.9

Equity ratio(%)

Mar 2022

46.01

Mar 2023

72.97

Mar 2024

59.6

Mar 2025

63.4

Earnings per share(JPY per share)

Mar 2022

6.77

Mar 2023

3.66

Mar 2024

-25.15

Mar 2025

8.04

Net assets per share(JPY per share)

Mar 2022

32.89

Mar 2023

77.07

Mar 2024

53.45

Mar 2025

61.91

Dividend per share(-)

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Payout ratio(-)

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Disclaimer

The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.

The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.